In‐Depth Optimization and Systematic Evaluation of a Recombinant AAV ‐Based Hepatic‐Targeted Gene Knockdown Murine Model
- 30 October 2025
- journal article
- Published by Wiley in The FASEB Journal
- Vol. 39 (21) , e71177
Abstract
Precise gene‐edited animal models are essential for preclinical liver research but are typically time‐consuming and costly. Here, a liver‐specific knockdown mouse model was developed based on a recombinant AAV (rAAV) tool, which is rapid and economical, with optimized delivery methods and systematically evaluated knockdown efficiency. Hepatic ischemia/reperfusion (IR) injury‐related genes ( Btg2 , Flrt3 , Klf4 ) were screened through GEO data mining. To knock down these genes, rAAV vectors featuring a liver‐specific promoter TBG669, Firefly luciferase (Fluc) for real‐time tracking, and miR30‐based regulatory elements were engineered. Delivery protocols were optimized through comparative analysis of reporting systems (GFP vs. Fluc), administration routes (tail vein vs. dorsal penile vein), and doses (half [2.5 × 10 11 GC] vs. full dose [5.0 × 10 11 GC]). Safety and knockdown efficiency were systematically assessed using histopathology, serum biochemistry, qRT‐PCR, and western blot analysis both in bulk liver tissue and single‐cell subsets. The optimized rAAV system achieved 100% hepatic infection rates with minimal off‐target expression. Dorsal penile vein injection simplified delivery without compromising efficacy. Full‐dose administration produced stronger bioluminescence by Week 4, with no adverse effects on organ function or histology. For knockdown efficiencies, Btg2 and Flrt3 mRNA and protein levels were reduced by > 50%, whereas Klf4 exhibited moderate suppression in bulk liver tissue. In single‐cell subsets, the three genes were all effectively knocked down in Kupffer cells, followed by hepatocytes and LSECs. A time‐ and cost‐efficient rAAV‐based hepatic gene knockdown murine model was established, enabling precise investigation of liver disease mechanisms and therapeutic development.Keywords
Funding Information
- National Natural Science Foundation of China (82400773)
- National Natural Science Foundation of China (82400745)
- National Natural Science Foundation of China (82170648)
- National Natural Science Foundation of China (82370646)
- National Natural Science Foundation of China (32201068)
- Natural Science Foundation of Henan Province (232300420257)
This publication has 41 references indexed in Scilit:
- Successful AAV8 gene therapy on hepatic ex situ machine perfusion for mitochondrial neurogastrointestinal encephalomyopathyJournal of Hepatology, 2025
- Robot-assisted liver surgery reduces complication rates while maintaining equivalent outcome quality compared to open liver surgeryEuropean Journal of Surgical Oncology, 2025
- Synergy of 5-aminolevulinate supplement and CX3CR1 suppression promotes liver regeneration via elevated IGF-1 signalingCell Reports, 2023
- mRNA and gene editing: Late breaking therapies in liver diseasesHepatology, 2022
- Nanobody-Enhanced Targeting of AAV Gene Therapy VectorsMolecular Therapy - Methods & Clinical Development, 2019
- Global liver disease burdens and research trends: Analysis from a Chinese perspectiveJournal of Hepatology, 2019
- Blood-brain barrier shuttle peptides enhance AAV transduction in the brain after systemic administrationBiomaterials, 2018
- The global burden of liver disease: The major impact of ChinaHepatology, 2014
- AAV-Mediated Liver-Directed Gene Therapy2011
- Toll–Like Receptor 2–Mediated Innate Immune Response in Human Nonparenchymal Liver Cells Toward Adeno–Associated Viral VectorsHepatology, 2011